Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Published:2024-04 Issue:4 Volume:7 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Ohama Hideko¹^ORCID,Hiraoka Atsushi¹^ORCID,Tada Toshifumi²^ORCID,Hirooka Masashi³,Kariyama Kazuya⁴^ORCID,Hatanaka Takeshi⁵^ORCID,Tani Joji⁶^ORCID,Takaguchi Koichi⁷,Atsukawa Masanori⁸^ORCID,Itobayashi Ei⁹,Nishimura Takashi¹⁰^ORCID,Tsuji Kunihiko¹¹,Tajiri Kazuto¹²,Ishikawa Toru¹³,Yasuda Satoshi¹⁴,Toyoda Hidenori¹⁴,Fukunishi Shinya¹⁰,Ogawa Chikara¹⁵,Kakizaki Satoru¹⁶,Shimada Noritomo¹⁷,Naganuma Atsushi¹⁸^ORCID,Kawata Kazuhito¹⁹,Kosaka Hisashi²⁰,Kuroda Hidekatsu²¹,Matono Tomomitsu²²,Yata Yutaka²³,Ochi Hironori²⁴,Tada Fujimasa¹,Nouso Kazuhiro⁴^ORCID,Morishita Asahiro⁶^ORCID,Itokawa Norio⁸,Okubo Tomomi⁸,Arai Taeang⁸,Tsutsui Akemi⁷,Nagano Takuya⁷,Yokohama Keisuke²⁵,Nishikawa Hiroki²⁵,Imai Michitaka¹²,Koizumi Yohei³,Nakamura Shinichiro²,Iijima Hiroko¹⁰,Kaibori Masaki²⁰,Hiasa Yoichi³^ORCID,Kumada Takashi²⁶,

Affiliation:

1. Ehime Prefectural Central Hospital, Gastroenterology Center Matsuyama Ehime Japan

2. Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Hyogo Japan

3. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Toon Ehime Japan

4. Department of Hepatology Okayama City Hospital Okayama Japan

5. Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Gunma Japan

6. Department of Gastroenterology and Hepatology Kagawa University Takamatsu Kagawa Japan

7. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Kagawa Japan

8. Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan

9. Department of Gastroenterology Asahi General Hospital Chiba Japan

10. Department of Gastroenterology and Hepatology Hyogo Medical University Kochi Hyogo Japan

11. Teine Keijinkai Hospital, Center of Gastroenterology Sapporo Hokkaido Japan

12. Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan

13. Department of Gastroenterology Toyama University Hospital Toyama Japan

14. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu Japan

15. Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Kagawa Japan

16. Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Gunma Japan

17. Division of Gastroenterology and Hepatology Otakanomori Hospital Chiba Japan

18. Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Gunma Japan

19. Hepatology Division, Department of Internal Medicine II Hamamatsu University School of Medicine Shizuoka Japan

20. Department of Surgery Kansai Medical University Osaka Japan

21. Division of Hepatology, Department of Internal Medicine, School of Medicine Iwate Medical University Iwate Japan

22. Department of Gastroenterology Hyogo Prefectural Harima‐Himeji General Medical Center Himeji Japan

23. Department of Gastroenterology Hanwa Memorial Hospital Osaka Japan

24. Japanese Red Cross Matsuyama Hospital, Hepato‐biliary Center Matsuyama Ehime Japan

25. Department of Gastroenterology Osaka Medical and Pharmaceutical University Osaka Japan

26. Department of Nursing Gifu Kyoritsu University Gifu Japan

Abstract

AbstractAimsThe aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment.MethodsA total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression‐free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c‐index) and Akaike information criterion (AIC) results.ResultsCox‐hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI‐De) scoring system. For IMABALI‐De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p < .001; AIC 2788.67, c‐index 0.699), while for CRAFITY scores of 0, 1, and 2, OS was 26.11, 20.29, and 11.32 months, respectively (p < .001; AIC 2864.54, c‐index 0.606). PFS periods for those IMABALI‐De scores were 21.75, 12.89, 9.18, 8.0, 5.0, and 3.75 months, respectively (p < .001; AIC 5203.32, c‐index 0.623) and for the CRAFITY scores were 10.32, 7.68, and 3.57 months, respectively (p < .001; AIC 5246.61, c‐index 0.574). As compared with CRAFITY score, IMABALI‐De score had better AIC and c‐index results for both OS and PFS.ConclusionThe present results indicated that the proposed IMABALI‐De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.2042

Reference48 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global Burden of 5 Major Types of Gastrointestinal Cancer

3. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

4. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

5. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements